News for BioInvent International AB (publ) (BOVNF)

EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ( XOMA), the biotech royalty aggregator, and BioInvent Internat

**media[637970,637971]**

BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

English Swedish ...

Feb 23, 2022 / 01:00PM GMTMartin Welschof - BioInvent International AB(publ)-CEO Thank you very much, and welcome, everybody, to our quarterly call. And I would

/PRNewswire/ -- "We are very pleased we have reached a second collaboration with MSD (Merck) that supports the expansion of the ongoing clinical trial program...

- Anti-TNFR2 antibody targets Treg mediated immunosuppression - Agreement supports the strong rationale for combining anti-TNFR2 and pembrolizumab...

/PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that it has entered into a second clinical trial...

LUND, Sweden, Aug. 6, 2021 /PRNewswire/ -- BioInvent International AB ('BioInvent') (Nasdaq Stockholm: BINV) today announced that it has entered i...

/PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and...

LUND, Sweden and STRASBOURG, France, May 27, 2021 /PRNewswire/ -- BioInvent International AB ('BioInvent') (Nasdaq Stockholm: BINV), a biotech com...